VANCOUVER, June 28 /PRNewswire/ - iCo Therapeutics Inc. announced today that Dr. Jason Slakter will join its strategic advisory team. An internationally renowned retinal specialist, Dr. Slakter currently practices at the Vitreous-Retina-Macula Consultants in New York. He is a Clinical Professor of Ophthalmology at the New York University School of Medicine and an attending surgeon and Surgeon Director at the Manhattan Eye, Ear and Throat Hospital.
“We are pleased to have Dr. Slakter join our advisory team,” said Andrew Rae, iCoTherapeutics’ President and Chief Executive Officer. “His clinical experience and expertise in the development and application of a variety of diagnostic techniques adds impressive bench strength to our team.”
Dr. Slakter’s expertise in macular disease diagnostics is extensive. He has played a leading role and is widely published in the development of digital indocyanine green angiography (ICG) for the evaluation and management of macular degeneration and chorioretinal inflammatory disease. He created and is the director of the Digital Angiography Reading Center, which serves as a key resource for numerous industry-sponsored studies. He has served as a Principal Investigator in the clinical trials for photodynamic therapy for the treatment of wet AMD and is currently conducting clinical studies for the treatment of central serous chorioretinopathy.
Dr. Slakter is a member of numerous medical organizations including the Macula and Retina Societies, and the American Society of Retinal Specialists. He is the Editor-in-Chief of Retinal Physician, is on the editorial board of Retina and serves as a scientific reviewer for major scientific ophthalmic journals. He is the recipient of a number of awards including the American Academy of Ophthalmology Honor Award, the Macula Society’s Richard and Hinda Rosenthal Award, and the Helen Keller Manhattan League Award.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments-areas such as the eye, spinal cord, or joints-where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: www.icotherapeutics.com
Business Development Contact: Finance, Investor Contact: Dr. John Clement, CT&DO Mr. John Meekison, CFO 778.688.0644 604.602.9414 Media Contact: Amanda Smith, Principal, Smith Biotech 778-846-4116
iCo Therapeutics Inc.
CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)688-0644; Finance, Investor Contact: Mr. John Meekison, CFO, (604)602-9414; Media Contact: Amanda Smith, Principal, Smith Biotech, (778)846-4116
